Pharma's Almanac

Engineering Biologics and Nanomedicines to Traverse the Blood–Brain Barrier

BBB

Apr 1, 2026

Engineering Biologics and Nanomedicines to Traverse the Blood–Brain Barrier

Engineering approaches that leverage receptor-mediated transport, ligand targeting, and nanocarrier delivery systems are transforming how therapeutics reach the brain, enabling complex biologics and nucleic acid therapies to cross the blood–brain barrier that has historically limited central nervous system drug development.

Carbon Footprint

Apr 30, 2026

Product Carbon Footprint: Enabling Product-Level Decarbonization in Biopharma

Product-level carbon footprinting uses life-cycle-based measurements at the batch level, delivering clear insights needed to prioritize and validate reduction strategies.

Digital Patient and Clinician Platforms are Transforming Clinical Research and Patient Outcomes

Patient Communities

Mar 19, 2026

Digital Patient and Clinician Platforms are Transforming Clinical Research and Patient Outcomes

PPD's Leslie Harrold and Thermo Fisher Scientific's Michael Atkinson explain how digital patient communities and longitudinal clinical registries are converging to connect lived experience with structured real-world evidence, enabling more inclusive clinical research, more informed care decisions, and a more holistic understanding of treatment outcomes.

Rewriting the Genetic Code: Designing Biologics with Noncanonical Amino Acids

GCE

Apr 20, 2026

Rewriting the Genetic Code: Designing Biologics with Noncanonical Amino Acids

Advances in genetic code expansion are enabling the incorporation of noncanonical amino acids into proteins, expanding the chemical capabilities of biologics and opening new possibilities for designing therapeutic proteins with precisely engineered functions.

Producing Therapies for the Brain: Manufacturing and Formulation Challenges for CNS Biologics

Neuro CMC

Apr 3, 2026

Producing Therapies for the Brain: Manufacturing and Formulation Challenges for CNS Biologics

Biologic therapies targeting CNS diseases CMC challenges because the blood–brain barrier and specialized delivery routes require integrated strategies that align therapeutic design, manufacturing platforms, formulation development, and administration technologies.

Accelerating ADC Analytical Method Development Through Platform Innovation

ADCs

Mar 23, 2026

Accelerating ADC Analytical Method Development Through Platform Innovation

Samsung Biologics’ platform-based analytical strategy enables faster, lower-risk ADC development by combining standardized yet adaptable methods to generate early CQA insights, streamline IND readiness, and support complex, evolving bioconjugate modalities.

Ovarian Cancer

Apr 21, 2026

Oncolytic Viruses at a Turning Point: Advancing Olvi-Vec for Advanced Ovarian Cancer

Jason Litten, M.D., Chief Medical Officer of Genelux, discusses the scientific rationale behind Olvi-Vec, the evolving role of viral immunotherapies in combination treatment strategies, and why the company believes the field may be approaching a turning point for oncolytic viruses.

Beyond Cytotoxins: Expanding the Payload Landscape for Antibody-Based Conjugates

Conjugate Payloads

May 1, 2026

Beyond Cytotoxins: Expanding the Payload Landscape for Antibody-Based Conjugates

Advances in bioconjugation chemistry and molecular therapeutics are transforming antibody-based conjugates from vehicles for targeted cytotoxic drugs into modular delivery platforms capable of transporting immune agonists, gene-modulating RNA therapeutics, and other emerging payload classes to specific cell populations.

Connecting Your Lab with an Integrated Digital Thread

Lab Platform

Apr 27, 2026

Connecting Your Lab with an Integrated Digital Thread

In this Q&A, Ryan Cawood, Ph.D., CEO and Co-Founder of Lab Thread, discusses how an integrated “digital thread” platform can connect laboratory workflows, data, and collaboration across research teams, improving visibility, reproducibility, and efficiency as life science organizations scale.

Engineering the Next Wave of CHO Performance With the S-CHOice® 2G Platform

CLD

Mar 11, 2026

Engineering the Next Wave of CHO Performance With the S-CHOice® 2G Platform

Wookjae Lee, Ph.D., and Migyeom Kim, Ph.D. describe how Samsung Biologics’ S-CHOice® 2G platform leverages targeted gene editing, multiparameter host screening, and integrated media and process optimization to consistently achieve double-digit antibody titers, enhancing manufacturability, scalability, and cost efficiency for next-generation biologics.

Spotlight

Nice Insight Pricing Reports

State of the Industry Report 2025

The Road to 30 Years

Latest

View all latest

From the Pharma's Almanac team

Fill-Finish

Mar 17, 2026

Digitalization and Automation Reshape Aseptic Fill–Finish Operations

Cardio–Renal–Metabolic Syndrome: Redefining Chronic Disease Through Integrated Treatment

CKM

Mar 16, 2026

Cardio–Renal–Metabolic Syndrome: Redefining Chronic Disease Through Integrated Treatment

FIll-Finish

Mar 12, 2026

Designing Flexible Fill-Finish Platforms for Small-Batch Precision Medicines

The Expanding Therapeutic Landscape in Chronic Kidney Disease

CKD

Mar 11, 2026

The Expanding Therapeutic Landscape in Chronic Kidney Disease

Human Factors in Aseptic Processing: Training, Behavior, and Risk Reduction

Aseptic Training

Mar 9, 2026

Human Factors in Aseptic Processing: Training, Behavior, and Risk Reduction

RABS or Isolators? Aligning Barrier Technology With Your Contamination Control Strategy

CCS

Mar 6, 2026

RABS or Isolators? Aligning Barrier Technology With Your Contamination Control Strategy

Building for Growth: Infrastructure, Governance, Talent, and Clinical Integration in European Biotech Clusters

EU Biotech

Mar 5, 2026

Building for Growth: Infrastructure, Governance, Talent, and Clinical Integration in European Biotech Clusters

Inside Europe’s Biotech Innovation Engines: Scale, Research Capacity, and Commercialization

EU Biotech

Mar 3, 2026

Inside Europe’s Biotech Innovation Engines: Scale, Research Capacity, and Commercialization

Allogeneic

Feb 19, 2026

Allogeneic CAR Cell Therapies: The Rise of Off-the-Shelf Immunotherapy

When Commercial Manufacturing Serves Dozens, Not Thousands

Ultra-Small-Scale

Feb 13, 2026

When Commercial Manufacturing Serves Dozens, Not Thousands

Opening the Blood–Brain Barrier: Device-Based Strategies for CNS Drug Delivery

BBB

Apr 2, 2026

Opening the Blood–Brain Barrier: Device-Based Strategies for CNS Drug Delivery

BBB

Apr 1, 2026

Engineering Biologics and Nanomedicines to Traverse the Blood–Brain Barrier

STATE OF THE INDUSTRY 2026

Small Molecules

State of the Industry 2026 Virtual Panel: Small Molecules

STATE OF THE INDUSTRY 2026

Advanced Therapies

Feb 2, 2026

State of the Industry 2026 Virtual Panel: Advanced Therapies (pt. 1)

Roundtable

View all roundtable

RoundTable Topics

Future Breakthroughs

What emerging technologies or scientific breakthroughs do you believe will most reshape biopharma in the next 10 years?

Kalim Saliba, Dotmatics

Steven Quay, M.D., Atossa Therapeutics

Tom Sellig, Adare Pharma Solutions

Cheryl Sturgis, Bionova Scientific

Maximillian Yeh, Cohance Lifesciences

In 2026 and moving forward, life science organizations will begin taking early but important steps toward creating a digital thread that spans the entire flow of how therapeutics are discovered, developed, and manufactured.

View all Answers

Roundtable

View all roundtable

Future Breakthroughs

What emerging technologies or scientific breakthroughs do you believe will most reshape biopharma in the next 10 years?

Kalim Saliba, Dotmatics

Steven Quay, M.D., Atossa Therapeutics

Tom Sellig, Adare Pharma Solutions

Cheryl Sturgis, Bionova Scientific

Maximillian Yeh, Cohance Lifesciences

View all Answers

RoundTable Topics

Future Breakthroughs

M&A

Innovations

GLP-1 Drugs

Small Molecules

SOTI 2026: Threats

SOTI 2026: Tools and Tech

SOTI 2026: Market Trends

PFDD

Rare Disease

CGT Commercialization

Precision Medicine

Women in Leadership

Digital Health

Biomanufacturing

Health Equity

Next-Generation Biologics

ARTIFICIAL INTELLIGENCE

SUPPLY CHAIN RESILIENCE 2025

PERSONALIZED MEDICINE

SUSTAINABILITY 2025

INDUSTRIAL INNOVATION

BIOSECURE

Global Access

Outsourcing Dynamics

Digital Connections

Investment Trends

Innovation

Regulatory

U.S. Market

Evolving Technologies

Personalized and Precision Medicine

Sustainability

Videos

View all videos

Software

Jul 24, 2025

DataHow is Advancing Bioprocess Development with AI-Driven Solutions

Through a mix of software, consulting, and hands-on training, DataHow empowers scientists and engineers to better understand their processes, generate insights from existing data, and work more effectively across projects.

Software

Jul 24, 2025

DataHow is Advancing Bioprocess Development with AI-Driven Solutions

Eldon James Corporation on Advancing Single-Use Solutions for Life Sciences and Healthcare

Clean Rooms

Jul 24, 2025

Eldon James Corporation on Advancing Single-Use Solutions for Life Sciences and Healthcare

How Simtra Helps Clients Overcome Challenges in Biologics Manufacturing

Injectables

May 7, 2025

How Simtra Helps Clients Overcome Challenges in Biologics Manufacturing

Examining Evolving Clean Room Requirements with Michael O'Rourke

Clean Rooms

May 2, 2025

Examining Evolving Clean Room Requirements with Michael O'Rourke

Packaging

May 30, 2025

At CS Analytical, Packaging is Everything

Single-Use Tech

May 6, 2025

SaniSure's Legacy of Innovation

Ecolab Strengthens Pharmaceutical Operations Through Smarter Cleaning Strategies

Decontamination

Jul 7, 2025

Ecolab Strengthens Pharmaceutical Operations Through Smarter Cleaning Strategies

Tech Transfer

May 19, 2025

A Firsthand Look at Lisure's M++ Tech Transfer Platform

Continuous Biomanufacturing with PAK BioSolutions

Bioprocessing

May 30, 2025

Continuous Biomanufacturing with PAK BioSolutions

Packaging

May 15, 2025

Wexler's Push for Sustainability in Packaging

Sterilization

May 12, 2025

Steri-Tek's Next-Gen Sterilization Techniques

Packaging

May 20, 2025

Stevanato Group's Evolution

DEEPER DIVE

Promise vs. Practice: Adaptive Control Systems in Cell and Gene Therapy Bioreactors

T Cell Manufacturing

Feb 9, 2026

Promise vs. Practice: Adaptive Control Systems in Cell and Gene Therapy Bioreactors

A Release-by-Exception Model for Cell Therapy Quality Decisions

Autologous

Feb 6, 2026

A Release-by-Exception Model for Cell Therapy Quality Decisions

Hybrid by Design: Automation Limits in Cell Therapy Manufacturing

CGT Automation

Feb 4, 2026

Hybrid by Design: Automation Limits in Cell Therapy Manufacturing

When Process Defines the Product: Managing Comparability in Cell and Gene Therapy Manufacturing

CGT Comparability

Feb 2, 2026

When Process Defines the Product: Managing Comparability in Cell and Gene Therapy Manufacturing

Regulatory Flexibility Clarified: Why Execution, Not Easing, Defines the Next Phase of CGT Manufacturing

CGT CMC

Feb 3, 2026

Regulatory Flexibility Clarified: Why Execution, Not Easing, Defines the Next Phase of CGT Manufacturing

A Look at Insect Cell Expression for Viral Vector and Virus-Like Particle Production

Insect Cell System

Feb 9, 2026

A Look at Insect Cell Expression for Viral Vector and Virus-Like Particle Production

Nice Insight’s State of the Industry 2026: Inside the CDMO Landscape

LEARN MORE

Nice Insight's State of the Industry 2025

LEARN MORE

Mammalian Cell Culture, Biologics: Market Insight, CDMO Pricing and Competitor Benchmarking

LEARN MORE

Microbial Fermentation, Biologics: Market Insight, CDMO Pricing and Benchmarking

LEARN MORE

Antibody–Drug Conjugate, ADC: Market Insight, CDMO Pricing and Competitor Benchmarking

LEARN MORE

Sterile Fill Finish: Market Insight, CDMO Pricing and Competitor Benchmarking

LEARN MORE

Gene Therapy: Market Insight, CDMO Pricing and Competitor Benchmarking

LEARN MORE

Cell Therapy: Market Insight, CDMO Pricing and Competitor Benchmarking

LEARN MORE

Messenger Ribonucleic Acid, mRNA: Market Insight, CDMO Pricing and Competitor Benchmarking

LEARN MORE

Plasmids Market Insight, CDMO Pricing and Competitor Benchmarking

LEARN MORE

Active Pharmaceutical Ingredients, API: Market Insight, CDMO Pricing and Competitor Benchmarking

LEARN MORE

Oral Solid Dose, OSD: Market Insight, CDMO Pricing and Benchmarking

LEARN MORE

The Road To Series

Software

Jul 24, 2025

DataHow is Advancing Bioprocess Development with AI-Driven Solutions

Through a mix of software, consulting, and hands-on training, DataHow empowers scientists and engineers to better understand their processes, generate insights from existing data, and work more effectively across projects.

Software

Jul 24, 2025

DataHow is Advancing Bioprocess Development with AI-Driven Solutions

Clean Rooms

Jul 24, 2025

Eldon James Corporation on Advancing Single-Use Solutions for Life Sciences and Healthcare

Injectables

May 7, 2025

How Simtra Helps Clients Overcome Challenges in Biologics Manufacturing

Clean Rooms

May 2, 2025

Examining Evolving Clean Room Requirements with Michael O'Rourke

Packaging

May 30, 2025

At CS Analytical, Packaging is Everything

Single-Use Tech

May 6, 2025

SaniSure's Legacy of Innovation

Decontamination

Jul 7, 2025

Ecolab Strengthens Pharmaceutical Operations Through Smarter Cleaning Strategies

Tech Transfer

May 19, 2025

A Firsthand Look at Lisure's M++ Tech Transfer Platform

Bioprocessing

May 30, 2025

Continuous Biomanufacturing with PAK BioSolutions

Packaging

May 15, 2025

Wexler's Push for Sustainability in Packaging

Sterilization

May 12, 2025

Steri-Tek's Next-Gen Sterilization Techniques

Packaging

May 20, 2025

Stevanato Group's Evolution

Mobile Navigation

Subscribe for the Newsletter

BBB

Engineering Biologics and Nanomedicines to Traverse the Blood–Brain Barrier

Carbon Footprint

Product Carbon Footprint: Enabling Product-Level Decarbonization in Biopharma

Product-level carbon footprinting uses life-cycle-based measurements at the batch level, delivering clear insights needed to prioritize and validate reduction strategies.

Patient Communities

Digital Patient and Clinician Platforms are Transforming Clinical Research and Patient Outcomes

GCE

Rewriting the Genetic Code: Designing Biologics with Noncanonical Amino Acids

Advances in genetic code expansion are enabling the incorporation of noncanonical amino acids into proteins, expanding the chemical capabilities of biologics and opening new possibilities for designing therapeutic proteins with precisely engineered functions.

Neuro CMC

Producing Therapies for the Brain: Manufacturing and Formulation Challenges for CNS Biologics

Biologic therapies targeting CNS diseases CMC challenges because the blood–brain barrier and specialized delivery routes require integrated strategies that align therapeutic design, manufacturing platforms, formulation development, and administration technologies.

ADCs

Accelerating ADC Analytical Method Development Through Platform Innovation

Samsung Biologics’ platform-based analytical strategy enables faster, lower-risk ADC development by combining standardized yet adaptable methods to generate early CQA insights, streamline IND readiness, and support complex, evolving bioconjugate modalities.

Ovarian Cancer

Oncolytic Viruses at a Turning Point: Advancing Olvi-Vec for Advanced Ovarian Cancer

Jason Litten, M.D., Chief Medical Officer of Genelux, discusses the scientific rationale behind Olvi-Vec, the evolving role of viral immunotherapies in combination treatment strategies, and why the company believes the field may be approaching a turning point for oncolytic viruses.

Conjugate Payloads

Beyond Cytotoxins: Expanding the Payload Landscape for Antibody-Based Conjugates

Lab Platform

Connecting Your Lab with an Integrated Digital Thread

In this Q&A, Ryan Cawood, Ph.D., CEO and Co-Founder of Lab Thread, discusses how an integrated “digital thread” platform can connect laboratory workflows, data, and collaboration across research teams, improving visibility, reproducibility, and efficiency as life science organizations scale.

CLD

Engineering the Next Wave of CHO Performance With the S-CHOice® 2G Platform

Recommended

Fill-Finish

FIll-Finish

Aseptic Training

Spotlight

Latest

Automation

Conjugate Payloads

Pathfinder

Carbon Footprint

Prion Signaling

Lab Platform

Neurology

Pathfinder

Subscribe for the Newsletter

From the Pharma's Almanac team

Fill-Finish

CKM

FIll-Finish

CKD

Aseptic Training

CCS

EU Biotech

EU Biotech

Allogeneic

Ultra-Small-Scale

BBB

BBB

STATE OF THE INDUSTRY 2026

Small Molecules

STATE OF THE INDUSTRY 2026

Advanced Therapies

Roundtable

Roundtable

Editor's Picks

Big Science

R&D AI

Pediatric Cancer

Insulin

Continuous Mfg

Abuse Deterrence

Autoimmune Diseases

Sex Differences

Gene Therapy

Continuous

Vaccines and the FDA

Biomanufacturing

Videos

Software

Through a mix of software, consulting, and hands-on training, DataHow empowers scientists and engineers to better understand their processes, generate insights from existing data, and work more effectively across projects.

Software

Clean Rooms